Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton South, Australia.
| Market Capitalization | $18.5291 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.037 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.05 |
| EBITDA | -15,722.398 |
| Profit Margin | 0 |
| Operating Margin TTM | -2.9201 |
| Return on Assets TTM | -0.4119 |
| Return on Equity TTM | -1.0742 |
| Revenue TTM | 5,711.222 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2020-06-30 | 0 | |||
| 2021-06-30 | 2.646 | 2.646 | 14,846.69 | |
| 2022-06-30 | 0 | 17,189.699 | ||
| 2023-06-30 | 0 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2020-06-30 | 0.1 | 0.1 | 64.01 | 34.01 | 0.1 | |
| 2021-06-30 | 22,410.199 | 36,504.86 | 11,374.172 | 0 | 3,683.39 | 37,366.641 |
| 2022-06-30 | 18,381.533 | 34,879.739 | 9,173.431 | 0 | 0 | 51,807.595 |
| 2023-06-30 | 2,362.654 | 22,492.09 | 16,414.868 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2020-06-30 | -153.619 | -81.617 | 0.24 | 0.1 | ||
| 2021-06-30 | -15,113.711 | -8,832.729 | 22,410.099 | 0.1 | 22,410.199 | |
| 2022-06-30 | -15,898.4 | -13,152.891 | -4,028.666 | 22,410.199 | 18,381.533 | |
| 2023-06-30 | -25,500.384 | -16,305.75 | -16,018.88 | 18,381.533 | 2,362.654 |